Alseres Pharmaceuticals Expands Sites For The First Stage Of The ALTROPANE(R) Phase III Clinical Trial Program

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced that seven sites for the first stage of the ALTROPANE(R) Parkinson’s or Essential Tremor - 2 (POET-2) Phase III clinical trial program are now open for patient enrollment. ALTROPANE molecular imaging agent is an investigational, diagnostic drug developed by Alseres to enable doctors to distinguish Parkinsonian Syndromes from non-Parkinsonian Syndromes in patients with tremor.

More: continued here

Filed under: Parkinson's Disease on May 15th, 2008